Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Operations (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Cash from Operations over the past 16 years, most recently at 5347000.0 for Q2 2025.

  • Quarterly results put Cash from Operations at 5347000.0 for Q2 2025, down 38.65% from a year ago — trailing twelve months through May 2025 was 206000.0 (down 180.16% YoY), and the annual figure for FY2025 was 206000.0, down 180.16%.
  • Cash from Operations for Q2 2025 was 5347000.0 at Lifecore Biomedical, Inc. \De\, up from 1200000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for LFCR hit a ceiling of 8716000.0 in Q2 2024 and a floor of 17310000.0 in Q1 2022.
  • Median Cash from Operations over the past 5 years was 1635000.0 (2022), compared with a mean of 2331555.56.
  • Biggest five-year swings in Cash from Operations: tumbled 656.49% in 2023 and later soared 485.32% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Cash from Operations stood at 4810000.0 in 2021, then skyrocketed by 51.08% to 2353000.0 in 2022, then skyrocketed by 154.74% to 1288000.0 in 2023, then plummeted by 576.71% to 6140000.0 in 2024, then soared by 187.08% to 5347000.0 in 2025.
  • The last three reported values for Cash from Operations were 5347000.0 (Q2 2025), 1200000.0 (Q1 2025), and 6140000.0 (Q4 2024) per Business Quant data.